Publications 2024
Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas
Med, 5 (6), 583-602.e5
DOI 10.1016/j.medj.2024.03.007, PubMed 38579729
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
Lancet (in press)
DOI 10.1016/S0140-6736(24)01315-1, PubMed 38971175
Hodgkin lymphoma: hypodense lesions in mediastinal masses
Sci Rep, 14 (1), 14591
DOI 10.1038/s41598-024-64253-8, PubMed 38918503